In 2020, cetuximab saratolacan, an antibody–dye conjugate that photosensitizes EGFR-bearing tumors, was approved in Japan for the treatment of head and neck cancer, demonstrating the potential of cetuximab binding domains to be used in alternative formats, such as antibody–drug conjugates and multipolicy antibodies [5]. The gene discussed is EGFR; the disease is head and neck cancer.